Frailty Status Affects the Decision for Long-Term Anticoagulation Therapy in Elderly Patients with Atrial Fibrillation

[1] Chugh SS(2014)Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study Circulation. 129 837-847

[2] Havmoeller R(2016)Efficacy and safety of novel anticoagulants in the elderly J Geriatr Cardiol. 13 718-723

[3] Narayanan K(2003)Rising rates of hospital admissions for atrial fibrillation Epidemiology. 14 666-672

[4] Singh D(2016)2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS Eur Heart J. 37 2893-2962

[5] Rienstra M(2016)The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation Eur Heart J. 37 1582-1590

[6] Benjamin EJ(2017)Thromboembolic risk, bleeding outcomes and effect of different antithrombotic strategies in very elderly patients with atrial fibrillation: a sub-analysis from the PREFER in AF (PREvention oF Thromboembolic Events-European Registry in Atrial Fibrillation) J Am Heart Assoc 6 e005657-150

[7] Karamichalakis N(2015)Stroke and major bleeding risk in elderly patients aged ≥ 75 years with atrial fibrillation: the Loire Valley atrial fibrillation project Stroke. 46 143-474

[8] Georgopoulos S(2001)Warfarin therapy for an octogenarian who has atrial fibrillation Ann Intern Med. 134 465-507

[9] Vlachos K(2017)Appropriateness of oral anticoagulants for the long-term treatment of atrial fibrillation in older people: results of an evidence-based review and international consensus validation process (OAC-FORTA 2016) Drugs Aging. 34 499-493

[10] Liatakis I(2013)Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients Europace. 15 486-1151

[1] Chugh SS(2014)Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study Circulation. 129 837-847

[2] Havmoeller R(2016)Efficacy and safety of novel anticoagulants in the elderly J Geriatr Cardiol. 13 718-723

[3] Narayanan K(2003)Rising rates of hospital admissions for atrial fibrillation Epidemiology. 14 666-672

[4] Singh D(2016)2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS Eur Heart J. 37 2893-2962

[5] Rienstra M(2016)The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation Eur Heart J. 37 1582-1590

[6] Benjamin EJ(2017)Thromboembolic risk, bleeding outcomes and effect of different antithrombotic strategies in very elderly patients with atrial fibrillation: a sub-analysis from the PREFER in AF (PREvention oF Thromboembolic Events-European Registry in Atrial Fibrillation) J Am Heart Assoc 6 e005657-150

[7] Karamichalakis N(2015)Stroke and major bleeding risk in elderly patients aged ≥ 75 years with atrial fibrillation: the Loire Valley atrial fibrillation project Stroke. 46 143-474

[8] Georgopoulos S(2001)Warfarin therapy for an octogenarian who has atrial fibrillation Ann Intern Med. 134 465-507

[9] Vlachos K(2017)Appropriateness of oral anticoagulants for the long-term treatment of atrial fibrillation in older people: results of an evidence-based review and international consensus validation process (OAC-FORTA 2016) Drugs Aging. 34 499-493

[10] Liatakis I(2013)Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients Europace. 15 486-1151